- Home
- ZYME vs CTLP Comparison
ZYME vs CTLP Comparison
Compare ZYME & CTLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- CTLP
- Stock Information
- Founded
- ZYME 2003
- CTLP 1992
- Country
- ZYME United States
- CTLP United States
- Employees
- ZYME N/A
- CTLP N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- CTLP EDP Services
- Sector
- ZYME Health Care
- CTLP Technology
- Exchange
- ZYME Nasdaq
- CTLP Nasdaq
- Market Cap
- ZYME 968.5M
- CTLP 797.4M
- IPO Year
- ZYME 2017
- CTLP N/A
- Fundamental
- Price
- ZYME $14.81
- CTLP $10.87
- Analyst Decision
- ZYME Buy
- CTLP Hold
- Analyst Count
- ZYME 7
- CTLP 5
- Target Price
- ZYME $20.00
- CTLP $11.50
- AVG Volume (30 Days)
- ZYME 453.7K
- CTLP 1.9M
- Earning Date
- ZYME 08-07-2025
- CTLP 09-10-2025
- Dividend Yield
- ZYME N/A
- CTLP N/A
- EPS Growth
- ZYME N/A
- CTLP 404.65
- EPS
- ZYME N/A
- CTLP 0.80
- Revenue
- ZYME $122,867,000.00
- CTLP $292,642,000.00
- Revenue This Year
- ZYME $107.76
- CTLP $15.44
- Revenue Next Year
- ZYME $2.35
- CTLP $15.82
- P/E Ratio
- ZYME N/A
- CTLP $13.59
- Revenue Growth
- ZYME 95.94
- CTLP 12.51
- 52 Week Low
- ZYME $9.03
- CTLP $5.82
- 52 Week High
- ZYME $17.70
- CTLP $11.36
- Technical
- Relative Strength Index (RSI)
- ZYME 62.78
- CTLP 46.97
- Support Level
- ZYME $13.48
- CTLP $10.83
- Resistance Level
- ZYME $15.35
- CTLP $10.88
- Average True Range (ATR)
- ZYME 0.58
- CTLP 0.06
- MACD
- ZYME 0.10
- CTLP -0.02
- Stochastic Oscillator
- ZYME 80.21
- CTLP 38.10
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About CTLP Cantaloupe Inc.
Cantaloupe Inc operates in the small ticket electronic payments industry. It provides wireless, cashless, micro-transactions, and networking services within the unattended Point of Sale (POS) market. Its products and services portfolio consists of ePort Cashless devices, eSuds, EnergyMisers, and Value-added services which include Loyalty and Prepaid, Intelligent Vending, and others. The company offers services to different industries covering car wash, taxi and transportation, laundry, vending, kiosk, amusement, and arcade. The company derives revenue from the sale or lease of equipment and services to the small ticket, unattended POS market, and the majority of its revenue is derived from subscription and transaction fees.